Regencell Bioscience's 15min chart shows KDJ Golden Cross, Bullish Marubozu pattern.

Regencell Bioscience's 15-minute chart has exhibited a KDJ Golden Cross and a Bullish Marubozu formation on October 13, 2022 at 10:00. This indicates a shift in the momentum of the stock price towards a more optimistic direction, with potential for further increases. The presence of buyers dominating the market and the ongoing bullish momentum suggests that the stock is likely to continue its upward trajectory.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has demonstrated a remarkable turnaround in its stock price, with a significant rebound following a tumultuous period. On October 13, 2022, the stock exhibited a KDJ Golden Cross and a Bullish Marubozu formation, indicating a shift in momentum towards a more optimistic direction Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1]. This technical analysis suggests that the stock is likely to continue its upward trajectory, driven by strong buying interest and sustained bullish momentum.

The stock's recent performance has been marked by volatility, with prices soaring from $1 to $84 before plummeting below $10. Despite these fluctuations, RGC has remained one of the most heavily traded biotech stocks on the Nasdaq, showcasing persistent investor fascination Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1]. After weeks of consolidation near $12, the stock found technical support at the 20-week simple moving average and began to rebound, reaching $20 on Tuesday, October 7, 2025 Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].

Regencell's origins are deeply personal, stemming from the health recovery story of COO James Chung. The company's mission combines traditional Chinese medicine with modern biomedical approaches, focusing on neurodegenerative and neuropsychological disorders. Despite its small team of 12 employees, Regencell has achieved a market capitalization of around $10 billion, highlighting the high-risk, high-reward nature of speculative biotech investing Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].

The company's latest rebound shows that investor appetite for high-volatility biotech stories remains strong, especially when technical levels and trading momentum align. However, questions about clinical progress, revenue generation, and regulatory milestones continue to loom large, underscoring the uncertainty that defines much of the biotech sector Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].